Specific price of amivantamab

Evantumumab (amivantamab) is an innovative antibody drug targeting dual targets of EGFR and MET. It occupies an increasingly important position in the treatment of non-small cell lung cancer (NSCLC). Its research and development background is to solve the clinical treatment problem of a special subtype of EGFR exon 20 insertion mutation. In the past, tyrosine kinase inhibitors targeting EGFR-sensitive mutations have been widely used, but their effects on exon 20 insertion mutations were not ideal. The approval of evantumumab has filled this gap.

In terms of indications, evantumumab is currently approved for two patient groups. The first category is patients with locally advanced or metastatic non-small cell lung cancer who are confirmed to have EGFR exon20 insertion mutations. As first-line treatment, it is often used in combination with carboplatin and pemetrexed. The second category is patients who have already received platinum-based chemotherapy and whose disease has progressed. At this time, evantumumab monotherapy can be used. The establishment of these indications allows patients to have more targeted treatment options in the context of precision medicine.

In terms of price, as an innovative biological agent, the price of evantumumab is generally high. At present, it has been approved for marketing in China, but it has not yet been included in the medical insurance catalog. Based on the specifications of 350mg/7mL, the price per box is approximately more than 7,000 yuan. The price of a single box of the original research version purchased through Hong Kong channels is more than 8,000 RMB. In overseas markets such as Europe, due to factors such as market pricing and exchange rates, the price of each box may be as high as 20,000 RMB. Since there are no generic versions of this drug on the market yet, most patients rely on the supply of original drugs, and the price difference has become a major obstacle to practical clinical application.

The high price of drugs not only reflects their R&D investment and complexity of production processes, but is also related to market patent protection and supply models. For patients, how to reduce the financial burden through medical insurance negotiations or assistance projects will be an important prerequisite for widespread application in the future.

Reference materials:https://www.rybrevant.com/